Your browser doesn't support javascript.
loading
Highly potent bispecific sybodies neutralize SARS-CoV-2
Justin D. Walter; Cedric A.J. Hutter; Alisa A. Garaeva; Melanie Scherer; Iwan Zimmermann; Marianne Wyss; Jan Rheinberger; Yelena Ruedin; Jennifer C. Earp; Pascal Egloff; Michèle Sorgenfrei; Lea Hürlimann; Imre Gonda; Gianmarco Meier; Sille Remm; Sujani Thavarasah; Gerrit van Geest; Rémy Bruggman; Gert Zimmer; Dirk J Slotboom; Cristina Paulino; Philippe Plattet; Markus A. Seeger.
Affiliation
  • Justin D. Walter; Institute of Medical Microbiology, University of Zurich
  • Cedric A.J. Hutter; Institute of Medical Microbiology, University of Zurich
  • Alisa A. Garaeva; Department of Membrane Enzymology at the Groningen Biomolecular Sciences and Biotechnology Institute, University of Groningen
  • Melanie Scherer; Division of Experimental and Clinical Research, Vetsuisse Faculty, University of Bern
  • Iwan Zimmermann; Institute of Medical Microbiology, University of Zurich and Linkster Therapeutics AG, Zurich
  • Marianne Wyss; Division of Experimental and Clinical Research, Vetsuisse Faculty, University of Bern
  • Jan Rheinberger; Department of Structural Biology at the Groningen Biomolecular Sciences and Biotechnology Institute, University of Groningen
  • Yelena Ruedin; Institute of Virology and Immunology, Vetsuisse Faculty, University of Bern and Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, Universi
  • Jennifer C. Earp; Institute of Medical Microbiology, University of Zurich
  • Pascal Egloff; Institute of Medical Microbiology, University of Zurich and Linkster Therapeutics AG, Zurich
  • Michèle Sorgenfrei; Institute of Medical Microbiology, University of Zurich
  • Lea Hürlimann; Institute of Medical Microbiology, University of Zurich
  • Imre Gonda; Institute of Medical Microbiology, University of Zurich
  • Gianmarco Meier; Institute of Medical Microbiology, University of Zurich
  • Sille Remm; Institute of Medical Microbiology, University of Zurich
  • Sujani Thavarasah; Institute of Medical Microbiology, University of Zurich
  • Gerrit van Geest; Interfaculty Bioinformatics Unit and Swiss Institute of Bioinformatics, University of Bern, Bern, Switzerland
  • Rémy Bruggman; Interfaculty Bioinformatics Unit and Swiss Institute of Bioinformatics, University of Bern, Bern, Switzerland
  • Gert Zimmer; Institute of Virology and Immunology, Vetsuisse Faculty, University of Bern and Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, Universit
  • Dirk J Slotboom; Department of Membrane Enzymology at the Groningen Biomolecular Sciences and Biotechnology Institute, University of Groningen
  • Cristina Paulino; Department of Membrane Enzymology at the Groningen Biomolecular Sciences and Biotechnology Institute, University of Groningen and Department of Structural Biol
  • Philippe Plattet; Division of Experimental and Clinical Research, Vetsuisse Faculty, University of Bern
  • Markus A. Seeger; Institute of Medical Microbiology, University of Zurich
Preprint in English | bioRxiv | ID: ppbiorxiv-376822
ABSTRACT
The ongoing COVID-19 pandemic represents an unprecedented global health crisis. Here, we report the identification of a synthetic nanobody (sybody) pair (Sb#15 and Sb#68) that can bind simultaneously to the SARS-CoV-2 spike-RBD and efficiently neutralize pseudotyped and live-viruses by interfering with ACE2 interaction. Two spatially-discrete epitopes identified by cryo-EM translated into the rational design of bispecific and tri-bispecific fusions constructs, exhibiting up to 100- and 1000-fold increase in neutralization potency. Cryo-EM of the sybody-spike complex further revealed a novel up-out RBD conformation. While resistant viruses emerged rapidly in the presence of single binders, no escape variants were observed in presence of the bispecific sybody. The multivalent bispecific constructs further increased the neutralization potency against globally-circulating SARS- CoV-2 variants of concern. Our study illustrates the power of multivalency and biparatopic nanobody fusions for the development of clinically relevant therapeutic strategies that mitigate the emergence of new SARS-CoV-2 escape mutants.
License
cc_by_nd
Full text: Available Collection: Preprints Database: bioRxiv Type of study: Prognostic study Language: English Year: 2020 Document type: Preprint
Full text: Available Collection: Preprints Database: bioRxiv Type of study: Prognostic study Language: English Year: 2020 Document type: Preprint
...